Global Non-Invasive Prenatal Testing Market

Non-Invasive Prenatal Testing Comprehensive Study by Type (High & Average Risk, Low Risk), Application (0-12 weeks, 13-24 weeks, 25-36 weeks), Consumables (Assay Kits & Reagents, Disposables), Instruments (Ultrasound Devices, Next-Generation Sequencing Systems, Polymerase Chain Reaction Instruments, Microarrays, Other Instruments), Testing (MaterniT21 PLUS, NIFTY, Harmony test, PrenaTest, Panorama test, Verifi, Others) Players and Region - Global Market Outlook to 2030

Non-Invasive Prenatal Testing Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 9.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Non-Invasive Prenatal Testing
According to the Center for Disease Control and Prevention, Down syndrome was the most common chromosomal disorder, as about 6000 babies are born with Down syndrome every year in the United States. Additionally, the Organization also stated in 2017, that older mothers were more likely to have a baby affected by Down syndrome than younger mothers. Noninvasive prenatal testing (NIPT), also known as noninvasive prenatal screening (NIPS), is a method of determining the risk that the fetus will be born with certain genetic abnormalities. The testing analyzes small fragments of DNA that are circulating in a pregnant woman's blood. NIPT is highly sensitive screening method for detecting specific chromosomal abnormalities, such as Patau syndrome (Trisomy13), Down syndrome (Trisomy 21), Turner Syndrome (Monosomy X), and Edwards syndrome (Trisomy 18), in the developing baby, from as early as week 10 of pregnancy.The Evolution of Prenatal testing, in the form of non-invasive tests serves as an intermediate step between Screening and Invasive tests in order to determine the probability of fetal abnormality is driving the Global Non-Invasive Prenatal Testing Market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR9.7%


The market is highly intense and fragmented with International and Regional market players. Several Companies and Research Oganizations have signed distribution agreements with test providers to be able to offer advanced products and services to the patients, which is creating a positive impact on the Global Non-Invasive Prenatal Testing market. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Non-Invasive Prenatal Testing market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GE Healthcare (United States), Koninklijke Philips N.V.(Netherlands), Illumina, Inc. (United States), Thermo Fisher Scientific, Inc.(United States), Perkinelmer, Inc. (United States), Sequenom Laboratories (United States), Roche Holding AG (Switzerland), Natera Inc. (United States) and LabCorp (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Ivitae (United Status), Agilent Technologies, Inc.(United States), BGI Genomics (China), Quest Diagnostics Incorporation (United States) and Berry Genomics Co.Ltd. (China).

Segmentation Overview
AMA Research has segmented the market of Global Non-Invasive Prenatal Testing market by Type (High & Average Risk and Low Risk), Application (0-12 weeks, 13-24 weeks and 25-36 weeks) and Region.



On the basis of geography, the market of Non-Invasive Prenatal Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. If we see Market by Consumables, the sub-segment i.e. Assay Kits & Reagents will boost the Non-Invasive Prenatal Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Instruments, the sub-segment i.e. Ultrasound Devices will boost the Non-Invasive Prenatal Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Testing, the sub-segment i.e. MaterniT21 PLUS will boost the Non-Invasive Prenatal Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The increasing number of Partnerships and Collaborations focused on innovative Genetic solution analysis, to support the education program, and for the better price and faster availability of tests and Less delineation between High and Average risk, which is expected to enhance the volumetric capabilities of the market.

Market Growth Drivers:
Increasing Incidence of Chromosome Syndrome and Genetic Abnormalities, Rising Healthcare Expenditure, Growing Demand for Early and Non-Invasive Fetal Testing Procedures and High Number of Reported Late Pregnancies.

Challenges:
Reliability of Test Results Especially in Obese Women.

Restraints:
Lack of Skilled Professionals and Cost Factor Associated with the treatment.

Opportunities:
Accelerated customer adoption of NIPT procedures coupled with the expansion in the Distribution services of the operating entities

Market Leaders and their expansionary development strategies
In February 2019, Invitae launched Non-Invasive Prenatal Screening offers integrated testing using the two most common prenatal genetic tests, with in-depth follow-up testing available for patients who need it. The company made the announcement in conjunction with the Society for Maternal-Fetal Medicine.
In March 2024, Igentify, a digital health company alleviating bottlenecks in the genetic testing process, launched of its Non-Invasive Prenatal Testing (NIPT) and Pharmacogenomics (PGx) offerings via the Digital Genetic Assistant platform. This new roll-out comes in addition to their Expanded Carrier Screening (ECS) offering.


Key Target Audience
Non-Invasive Prenatal Testing Manufacturers, Government & Regulatory Agencies, Potential Investors, Research Organizations and Pharamaceutical Companies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • High & Average Risk
  • Low Risk
By Application
  • 0-12 weeks
  • 13-24 weeks
  • 25-36 weeks
By Consumables
  • Assay Kits & Reagents
  • Disposables

By Instruments
  • Ultrasound Devices
  • Next-Generation Sequencing Systems
  • Polymerase Chain Reaction Instruments
  • Microarrays
  • Other Instruments

By Testing
  • MaterniT21 PLUS
  • NIFTY
  • Harmony test
  • PrenaTest
  • Panorama test
  • Verifi
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of Chromosome Syndrome and Genetic Abnormalities
      • 3.2.2. Rising Healthcare Expenditure
      • 3.2.3. Growing Demand for Early and Non-Invasive Fetal Testing Procedures
      • 3.2.4. High Number of Reported Late Pregnancies.
    • 3.3. Market Challenges
      • 3.3.1. Reliability of Test Results Especially in Obese Women.
    • 3.4. Market Trends
      • 3.4.1. The increasing number of Partnerships and Collaborations focused on innovative Genetic solution analysis, to support the education program, and for the better price and faster availability of tests
      • 3.4.2. Less delineation between High and Average risk, which is expected to enhance the volumetric capabilities of the market.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Non-Invasive Prenatal Testing, by Type, Application, Consumables, Instruments, Testing and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Non-Invasive Prenatal Testing (Value)
      • 5.2.1. Global Non-Invasive Prenatal Testing by: Type (Value)
        • 5.2.1.1. High & Average Risk
        • 5.2.1.2. Low Risk
      • 5.2.2. Global Non-Invasive Prenatal Testing by: Application (Value)
        • 5.2.2.1. 0-12 weeks
        • 5.2.2.2. 13-24 weeks
        • 5.2.2.3. 25-36 weeks
      • 5.2.3. Global Non-Invasive Prenatal Testing by: Consumables (Value)
        • 5.2.3.1. Assay Kits & Reagents
        • 5.2.3.2. Disposables
      • 5.2.4. Global Non-Invasive Prenatal Testing by: Instruments (Value)
        • 5.2.4.1. Ultrasound Devices
        • 5.2.4.2. Next-Generation Sequencing Systems
        • 5.2.4.3. Polymerase Chain Reaction Instruments
        • 5.2.4.4. Microarrays
        • 5.2.4.5. Other Instruments
      • 5.2.5. Global Non-Invasive Prenatal Testing by: Testing (Value)
        • 5.2.5.1. MaterniT21 PLUS
        • 5.2.5.2. NIFTY
        • 5.2.5.3. Harmony test
        • 5.2.5.4. PrenaTest
        • 5.2.5.5. Panorama test
        • 5.2.5.6. Verifi
        • 5.2.5.7. Others
      • 5.2.6. Global Non-Invasive Prenatal Testing Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Non-Invasive Prenatal Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GE Healthcare (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Koninklijke Philips N.V.(Netherlands)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Illumina, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Thermo Fisher Scientific, Inc.(United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Perkinelmer, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sequenom Laboratories (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Roche Holding AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Natera Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. LabCorp (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Non-Invasive Prenatal Testing Sale, by Type, Application, Consumables, Instruments, Testing and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Non-Invasive Prenatal Testing (Value)
      • 7.2.1. Global Non-Invasive Prenatal Testing by: Type (Value)
        • 7.2.1.1. High & Average Risk
        • 7.2.1.2. Low Risk
      • 7.2.2. Global Non-Invasive Prenatal Testing by: Application (Value)
        • 7.2.2.1. 0-12 weeks
        • 7.2.2.2. 13-24 weeks
        • 7.2.2.3. 25-36 weeks
      • 7.2.3. Global Non-Invasive Prenatal Testing by: Consumables (Value)
        • 7.2.3.1. Assay Kits & Reagents
        • 7.2.3.2. Disposables
      • 7.2.4. Global Non-Invasive Prenatal Testing by: Instruments (Value)
        • 7.2.4.1. Ultrasound Devices
        • 7.2.4.2. Next-Generation Sequencing Systems
        • 7.2.4.3. Polymerase Chain Reaction Instruments
        • 7.2.4.4. Microarrays
        • 7.2.4.5. Other Instruments
      • 7.2.5. Global Non-Invasive Prenatal Testing by: Testing (Value)
        • 7.2.5.1. MaterniT21 PLUS
        • 7.2.5.2. NIFTY
        • 7.2.5.3. Harmony test
        • 7.2.5.4. PrenaTest
        • 7.2.5.5. Panorama test
        • 7.2.5.6. Verifi
        • 7.2.5.7. Others
      • 7.2.6. Global Non-Invasive Prenatal Testing Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Non-Invasive Prenatal Testing: by Type(USD Million)
  • Table 2. Non-Invasive Prenatal Testing High & Average Risk , by Region USD Million (2018-2023)
  • Table 3. Non-Invasive Prenatal Testing Low Risk , by Region USD Million (2018-2023)
  • Table 4. Non-Invasive Prenatal Testing: by Application(USD Million)
  • Table 5. Non-Invasive Prenatal Testing 0-12 weeks , by Region USD Million (2018-2023)
  • Table 6. Non-Invasive Prenatal Testing 13-24 weeks , by Region USD Million (2018-2023)
  • Table 7. Non-Invasive Prenatal Testing 25-36 weeks , by Region USD Million (2018-2023)
  • Table 8. Non-Invasive Prenatal Testing: by Consumables(USD Million)
  • Table 9. Non-Invasive Prenatal Testing Assay Kits & Reagents , by Region USD Million (2018-2023)
  • Table 10. Non-Invasive Prenatal Testing Disposables , by Region USD Million (2018-2023)
  • Table 11. Non-Invasive Prenatal Testing: by Instruments(USD Million)
  • Table 12. Non-Invasive Prenatal Testing Ultrasound Devices , by Region USD Million (2018-2023)
  • Table 13. Non-Invasive Prenatal Testing Next-Generation Sequencing Systems , by Region USD Million (2018-2023)
  • Table 14. Non-Invasive Prenatal Testing Polymerase Chain Reaction Instruments , by Region USD Million (2018-2023)
  • Table 15. Non-Invasive Prenatal Testing Microarrays , by Region USD Million (2018-2023)
  • Table 16. Non-Invasive Prenatal Testing Other Instruments , by Region USD Million (2018-2023)
  • Table 17. Non-Invasive Prenatal Testing: by Testing(USD Million)
  • Table 18. Non-Invasive Prenatal Testing MaterniT21 PLUS , by Region USD Million (2018-2023)
  • Table 19. Non-Invasive Prenatal Testing NIFTY , by Region USD Million (2018-2023)
  • Table 20. Non-Invasive Prenatal Testing Harmony test , by Region USD Million (2018-2023)
  • Table 21. Non-Invasive Prenatal Testing PrenaTest , by Region USD Million (2018-2023)
  • Table 22. Non-Invasive Prenatal Testing Panorama test , by Region USD Million (2018-2023)
  • Table 23. Non-Invasive Prenatal Testing Verifi , by Region USD Million (2018-2023)
  • Table 24. Non-Invasive Prenatal Testing Others , by Region USD Million (2018-2023)
  • Table 25. South America Non-Invasive Prenatal Testing, by Country USD Million (2018-2023)
  • Table 26. South America Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 27. South America Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 28. South America Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 29. South America Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 30. South America Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 31. Brazil Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 32. Brazil Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 33. Brazil Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 34. Brazil Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 35. Brazil Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 36. Argentina Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 37. Argentina Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 38. Argentina Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 39. Argentina Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 40. Argentina Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 41. Rest of South America Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 42. Rest of South America Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 43. Rest of South America Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 44. Rest of South America Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 45. Rest of South America Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 46. Asia Pacific Non-Invasive Prenatal Testing, by Country USD Million (2018-2023)
  • Table 47. Asia Pacific Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 48. Asia Pacific Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 49. Asia Pacific Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 50. Asia Pacific Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 51. Asia Pacific Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 52. China Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 53. China Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 54. China Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 55. China Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 56. China Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 57. Japan Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 58. Japan Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 59. Japan Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 60. Japan Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 61. Japan Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 62. India Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 63. India Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 64. India Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 65. India Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 66. India Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 67. South Korea Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 68. South Korea Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 69. South Korea Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 70. South Korea Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 71. South Korea Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 72. Taiwan Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 73. Taiwan Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 74. Taiwan Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 75. Taiwan Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 76. Taiwan Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 77. Australia Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 78. Australia Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 79. Australia Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 80. Australia Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 81. Australia Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 87. Europe Non-Invasive Prenatal Testing, by Country USD Million (2018-2023)
  • Table 88. Europe Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 89. Europe Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 90. Europe Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 91. Europe Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 92. Europe Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 93. Germany Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 94. Germany Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 95. Germany Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 96. Germany Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 97. Germany Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 98. France Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 99. France Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 100. France Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 101. France Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 102. France Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 103. Italy Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 104. Italy Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 105. Italy Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 106. Italy Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 107. Italy Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 108. United Kingdom Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 109. United Kingdom Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 110. United Kingdom Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 111. United Kingdom Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 112. United Kingdom Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 113. Netherlands Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 114. Netherlands Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 115. Netherlands Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 116. Netherlands Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 117. Netherlands Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 118. Rest of Europe Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 119. Rest of Europe Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 120. Rest of Europe Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 121. Rest of Europe Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 122. Rest of Europe Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 123. MEA Non-Invasive Prenatal Testing, by Country USD Million (2018-2023)
  • Table 124. MEA Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 125. MEA Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 126. MEA Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 127. MEA Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 128. MEA Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 129. Middle East Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 130. Middle East Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 131. Middle East Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 132. Middle East Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 133. Middle East Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 134. Africa Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 135. Africa Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 136. Africa Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 137. Africa Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 138. Africa Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 139. North America Non-Invasive Prenatal Testing, by Country USD Million (2018-2023)
  • Table 140. North America Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 141. North America Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 142. North America Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 143. North America Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 144. North America Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 145. United States Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 146. United States Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 147. United States Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 148. United States Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 149. United States Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 150. Canada Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 151. Canada Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 152. Canada Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 153. Canada Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 154. Canada Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 155. Mexico Non-Invasive Prenatal Testing, by Type USD Million (2018-2023)
  • Table 156. Mexico Non-Invasive Prenatal Testing, by Application USD Million (2018-2023)
  • Table 157. Mexico Non-Invasive Prenatal Testing, by Consumables USD Million (2018-2023)
  • Table 158. Mexico Non-Invasive Prenatal Testing, by Instruments USD Million (2018-2023)
  • Table 159. Mexico Non-Invasive Prenatal Testing, by Testing USD Million (2018-2023)
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Non-Invasive Prenatal Testing: by Type(USD Million)
  • Table 170. Non-Invasive Prenatal Testing High & Average Risk , by Region USD Million (2025-2030)
  • Table 171. Non-Invasive Prenatal Testing Low Risk , by Region USD Million (2025-2030)
  • Table 172. Non-Invasive Prenatal Testing: by Application(USD Million)
  • Table 173. Non-Invasive Prenatal Testing 0-12 weeks , by Region USD Million (2025-2030)
  • Table 174. Non-Invasive Prenatal Testing 13-24 weeks , by Region USD Million (2025-2030)
  • Table 175. Non-Invasive Prenatal Testing 25-36 weeks , by Region USD Million (2025-2030)
  • Table 176. Non-Invasive Prenatal Testing: by Consumables(USD Million)
  • Table 177. Non-Invasive Prenatal Testing Assay Kits & Reagents , by Region USD Million (2025-2030)
  • Table 178. Non-Invasive Prenatal Testing Disposables , by Region USD Million (2025-2030)
  • Table 179. Non-Invasive Prenatal Testing: by Instruments(USD Million)
  • Table 180. Non-Invasive Prenatal Testing Ultrasound Devices , by Region USD Million (2025-2030)
  • Table 181. Non-Invasive Prenatal Testing Next-Generation Sequencing Systems , by Region USD Million (2025-2030)
  • Table 182. Non-Invasive Prenatal Testing Polymerase Chain Reaction Instruments , by Region USD Million (2025-2030)
  • Table 183. Non-Invasive Prenatal Testing Microarrays , by Region USD Million (2025-2030)
  • Table 184. Non-Invasive Prenatal Testing Other Instruments , by Region USD Million (2025-2030)
  • Table 185. Non-Invasive Prenatal Testing: by Testing(USD Million)
  • Table 186. Non-Invasive Prenatal Testing MaterniT21 PLUS , by Region USD Million (2025-2030)
  • Table 187. Non-Invasive Prenatal Testing NIFTY , by Region USD Million (2025-2030)
  • Table 188. Non-Invasive Prenatal Testing Harmony test , by Region USD Million (2025-2030)
  • Table 189. Non-Invasive Prenatal Testing PrenaTest , by Region USD Million (2025-2030)
  • Table 190. Non-Invasive Prenatal Testing Panorama test , by Region USD Million (2025-2030)
  • Table 191. Non-Invasive Prenatal Testing Verifi , by Region USD Million (2025-2030)
  • Table 192. Non-Invasive Prenatal Testing Others , by Region USD Million (2025-2030)
  • Table 193. South America Non-Invasive Prenatal Testing, by Country USD Million (2025-2030)
  • Table 194. South America Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 195. South America Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 196. South America Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 197. South America Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 198. South America Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 199. Brazil Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 200. Brazil Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 201. Brazil Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 202. Brazil Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 203. Brazil Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 204. Argentina Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 205. Argentina Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 206. Argentina Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 207. Argentina Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 208. Argentina Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 209. Rest of South America Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 210. Rest of South America Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 211. Rest of South America Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 212. Rest of South America Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 213. Rest of South America Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 214. Asia Pacific Non-Invasive Prenatal Testing, by Country USD Million (2025-2030)
  • Table 215. Asia Pacific Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 216. Asia Pacific Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 217. Asia Pacific Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 218. Asia Pacific Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 219. Asia Pacific Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 220. China Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 221. China Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 222. China Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 223. China Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 224. China Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 225. Japan Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 226. Japan Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 227. Japan Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 228. Japan Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 229. Japan Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 230. India Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 231. India Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 232. India Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 233. India Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 234. India Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 235. South Korea Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 236. South Korea Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 237. South Korea Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 238. South Korea Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 239. South Korea Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 240. Taiwan Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 241. Taiwan Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 242. Taiwan Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 243. Taiwan Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 244. Taiwan Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 245. Australia Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 246. Australia Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 247. Australia Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 248. Australia Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 249. Australia Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 250. Rest of Asia-Pacific Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 251. Rest of Asia-Pacific Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 252. Rest of Asia-Pacific Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 253. Rest of Asia-Pacific Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 254. Rest of Asia-Pacific Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 255. Europe Non-Invasive Prenatal Testing, by Country USD Million (2025-2030)
  • Table 256. Europe Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 257. Europe Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 258. Europe Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 259. Europe Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 260. Europe Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 261. Germany Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 262. Germany Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 263. Germany Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 264. Germany Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 265. Germany Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 266. France Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 267. France Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 268. France Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 269. France Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 270. France Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 271. Italy Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 272. Italy Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 273. Italy Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 274. Italy Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 275. Italy Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 276. United Kingdom Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 277. United Kingdom Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 278. United Kingdom Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 279. United Kingdom Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 280. United Kingdom Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 281. Netherlands Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 282. Netherlands Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 283. Netherlands Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 284. Netherlands Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 285. Netherlands Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 286. Rest of Europe Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 287. Rest of Europe Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 288. Rest of Europe Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 289. Rest of Europe Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 290. Rest of Europe Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 291. MEA Non-Invasive Prenatal Testing, by Country USD Million (2025-2030)
  • Table 292. MEA Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 293. MEA Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 294. MEA Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 295. MEA Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 296. MEA Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 297. Middle East Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 298. Middle East Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 299. Middle East Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 300. Middle East Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 301. Middle East Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 302. Africa Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 303. Africa Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 304. Africa Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 305. Africa Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 306. Africa Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 307. North America Non-Invasive Prenatal Testing, by Country USD Million (2025-2030)
  • Table 308. North America Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 309. North America Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 310. North America Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 311. North America Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 312. North America Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 313. United States Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 314. United States Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 315. United States Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 316. United States Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 317. United States Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 318. Canada Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 319. Canada Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 320. Canada Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 321. Canada Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 322. Canada Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 323. Mexico Non-Invasive Prenatal Testing, by Type USD Million (2025-2030)
  • Table 324. Mexico Non-Invasive Prenatal Testing, by Application USD Million (2025-2030)
  • Table 325. Mexico Non-Invasive Prenatal Testing, by Consumables USD Million (2025-2030)
  • Table 326. Mexico Non-Invasive Prenatal Testing, by Instruments USD Million (2025-2030)
  • Table 327. Mexico Non-Invasive Prenatal Testing, by Testing USD Million (2025-2030)
  • Table 328. Research Programs/Design for This Report
  • Table 329. Key Data Information from Secondary Sources
  • Table 330. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Non-Invasive Prenatal Testing: by Type USD Million (2018-2023)
  • Figure 5. Global Non-Invasive Prenatal Testing: by Application USD Million (2018-2023)
  • Figure 6. Global Non-Invasive Prenatal Testing: by Consumables USD Million (2018-2023)
  • Figure 7. Global Non-Invasive Prenatal Testing: by Instruments USD Million (2018-2023)
  • Figure 8. Global Non-Invasive Prenatal Testing: by Testing USD Million (2018-2023)
  • Figure 9. South America Non-Invasive Prenatal Testing Share (%), by Country
  • Figure 10. Asia Pacific Non-Invasive Prenatal Testing Share (%), by Country
  • Figure 11. Europe Non-Invasive Prenatal Testing Share (%), by Country
  • Figure 12. MEA Non-Invasive Prenatal Testing Share (%), by Country
  • Figure 13. North America Non-Invasive Prenatal Testing Share (%), by Country
  • Figure 14. Global Non-Invasive Prenatal Testing share by Players 2023 (%)
  • Figure 15. Global Non-Invasive Prenatal Testing share by Players (Top 3) 2023(%)
  • Figure 16. Global Non-Invasive Prenatal Testing share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 19. GE Healthcare (United States) Revenue: by Geography 2023
  • Figure 20. Koninklijke Philips N.V.(Netherlands) Revenue, Net Income and Gross profit
  • Figure 21. Koninklijke Philips N.V.(Netherlands) Revenue: by Geography 2023
  • Figure 22. Illumina, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Illumina, Inc. (United States) Revenue: by Geography 2023
  • Figure 24. Thermo Fisher Scientific, Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 25. Thermo Fisher Scientific, Inc.(United States) Revenue: by Geography 2023
  • Figure 26. Perkinelmer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Perkinelmer, Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Sequenom Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 29. Sequenom Laboratories (United States) Revenue: by Geography 2023
  • Figure 30. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 32. Natera Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Natera Inc. (United States) Revenue: by Geography 2023
  • Figure 34. LabCorp (United States) Revenue, Net Income and Gross profit
  • Figure 35. LabCorp (United States) Revenue: by Geography 2023
  • Figure 36. Global Non-Invasive Prenatal Testing: by Type USD Million (2025-2030)
  • Figure 37. Global Non-Invasive Prenatal Testing: by Application USD Million (2025-2030)
  • Figure 38. Global Non-Invasive Prenatal Testing: by Consumables USD Million (2025-2030)
  • Figure 39. Global Non-Invasive Prenatal Testing: by Instruments USD Million (2025-2030)
  • Figure 40. Global Non-Invasive Prenatal Testing: by Testing USD Million (2025-2030)
  • Figure 41. South America Non-Invasive Prenatal Testing Share (%), by Country
  • Figure 42. Asia Pacific Non-Invasive Prenatal Testing Share (%), by Country
  • Figure 43. Europe Non-Invasive Prenatal Testing Share (%), by Country
  • Figure 44. MEA Non-Invasive Prenatal Testing Share (%), by Country
  • Figure 45. North America Non-Invasive Prenatal Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GE Healthcare (United States)
  • Koninklijke Philips N.V.(Netherlands)
  • Illumina, Inc. (United States)
  • Thermo Fisher Scientific, Inc.(United States)
  • Perkinelmer, Inc. (United States)
  • Sequenom Laboratories (United States)
  • Roche Holding AG (Switzerland)
  • Natera Inc. (United States)
  • LabCorp (United States)
Additional players considered in the study are as follows:
Ivitae (United Status) , Agilent Technologies, Inc.(United States) , BGI Genomics (China) , Quest Diagnostics Incorporation (United States) , Berry Genomics Co.Ltd. (China)
Select User Access Type

Key Highlights of Report


Mar 2024 213 Pages 82 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Non-Invasive Prenatal Testing Market Quantitative research analysis
Global Non-Invasive Prenatal Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GE Healthcare (United States), Koninklijke Philips N.V.(Netherlands), Illumina, Inc. (United States), Thermo Fisher Scientific, Inc.(United States), Perkinelmer, Inc. (United States), Sequenom Laboratories (United States), Roche Holding AG (Switzerland), Natera Inc. (United States) and LabCorp (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The increasing number of Partnerships and Collaborations focused on innovative Genetic solution analysis, to support the education program, and for the better price and faster availability of tests " is seen as one of major influencing trends for Non-Invasive Prenatal Testing Market during projected period 2023-2030.
The Non-Invasive Prenatal Testing market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Non-Invasive Prenatal Testing Market Report?

Have a Query? Click Here

Other Related Reports

Nursing Home Chair Comprehensive Study by Type (Manual Nursing Home Chair, Electric Nursing Home Chair), Application (Old Man Using, Patient Using, Other), Sales Channel (Online, Offline), Frame Mate...
$ 3450
Medical Foam Comprehensive Study by Type (Polyurethane, Polystyrene, Polyolefin), Application (Medical Packaging, Medical Devices & Components, Prosthetics & Wound Care), Distribution Channel (Online...
$ 3450
Specialty Gases For Healthcare Comprehensive Study by Application (Analytical and Laboratory, Sterilization, Others), Gas Type (Atmospheric Gases, Noble Gases, Carbon-Based Gases, Halogen-Based Gases...
$ 3650
Wearable EEG Monitors Comprehensive Study by Type (Portable, Compact), Application (Neuromonitoring, Monitor, Others), Sales Channels (Direct Sales, In Direct Sales), Channels (5-Channel Type, 14-Cha...
$ 3450
Digital Impression Systems Comprehensive Study by Type (Standalone Systems, Portable System), Application (Orthodontics, Restorative Dentistry, Others) Players and Region - Global Market Outlook to 2...
$ 3500
Personal Mobility Devices Comprehensive Study by Type (Canes, • Quad, • Forearm, Crutches, • Auxilarry, • Lofstrand, • Platform, Walkers, • Rollaters, • Cane Hybrid, Wheelchair, Mobility Scooter, Oth...
$ 3750